Study identifier:D133FR00197
ClinicalTrials.gov identifier:NCT06125314
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter, Non-Interventional, Retrospective Study Aims to Estimate the Prevalence and Describe the Clinical Manifestations of HER2-Low Breast Cancer Reported in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2- Negative from Patient Medical Records in The Gulf Council Cooperation Region
Breast Neoplasms
Phase 4
No
-
Female
385
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|